Literature DB >> 22584579

Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases.

Douglas E Linn1, Xi Yang, Yingqiu Xie, Alan Alfano, Dhanraj Deshmukh, Xin Wang, Hermela Shimelis, Hegang Chen, Wei Li, Kexin Xu, Mingyuan Chen, Yun Qiu.   

Abstract

Androgen receptor (AR) plays a pivotal role in prostate cancer. Regulation of AR transcriptional activity by post-translational modifications, such as phosphorylation by multiple kinases, is well documented. Here, we report that two PIM-1 kinase isoforms which are up-regulated during prostate cancer progression, namely PIM-1S and PIM-1L, modulate AR stability and transcriptional activity through differentially phosphorylating AR at serine 213 (Ser-213) and threonine 850 (Thr-850). Although both kinases are capable of interacting with and phosphorylating AR at Ser-213, only PIM-1L could phosphorylate Thr-850. We also showed that PIM-1S induced Ser-213 phosphorylation destabilizes AR by recruiting the ubiquitin E3 ligase Mdm2 and promotes AR degradation in a cell cycle-dependent manner, while PIM-1L-induced Thr-850 phosphorylation stabilizes AR by recruiting the ubiquitin E3 ligase RNF6 and promotes AR-mediated transcription under low-androgen conditions. Furthermore, both PIM-1 isoforms could promote prostate cancer cell growth under low-androgen conditions. Our data suggest that these kinases regulate AR stability and transcriptional activity through recruitment of different functional partners in a phosphorylation-dependent manner. As AR turnover has been previously shown to be critical for cell cycle progression in prostate cancer cells, PIM-1 kinase isoforms may promote prostate cancer cell growth, at least in part, through modulating AR activity via distinct mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22584579      PMCID: PMC3391098          DOI: 10.1074/jbc.M111.338350

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  75 in total

1.  Sequence and structure-based prediction of eukaryotic protein phosphorylation sites.

Authors:  N Blom; S Gammeltoft; S Brunak
Journal:  J Mol Biol       Date:  1999-12-17       Impact factor: 5.469

2.  Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.

Authors:  Bojie Dai; Hege Chen; Shengjie Guo; Xi Yang; Douglas E Linn; Feng Sun; Wei Li; Zhiyong Guo; Kexin Xu; Oekyung Kim; Xiangtian Kong; Jonathan Melamed; Shaopeng Qiu; Hegang Chen; Yun Qiu
Journal:  Cancer Res       Date:  2010-06-22       Impact factor: 12.701

3.  Adhesion signaling by a novel mitotic substrate of src kinases.

Authors:  Ami S Bhatt; Hediye Erdjument-Bromage; Paul Tempst; Charles S Craik; Mark M Moasser
Journal:  Oncogene       Date:  2005-08-11       Impact factor: 9.867

4.  Post-translational modification of the androgen receptor.

Authors:  Daniel Gioeli; Bryce M Paschal
Journal:  Mol Cell Endocrinol       Date:  2011-07-24       Impact factor: 4.102

5.  CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation.

Authors:  Vicki Gordon; Shriti Bhadel; Winfried Wunderlich; JoAnn Zhang; Scott B Ficarro; Sahana A Mollah; Jeffrey Shabanowitz; Donald F Hunt; Ioannis Xenarios; William C Hahn; Mark Conaway; Michael F Carey; Daniel Gioeli
Journal:  Mol Endocrinol       Date:  2010-10-27

6.  Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1).

Authors:  N Koike; H Maita; T Taira; H Ariga; S M Iguchi-Ariga
Journal:  FEBS Lett       Date:  2000-02-04       Impact factor: 4.124

7.  Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells.

Authors:  Xi Yang; Zhiyong Guo; Feng Sun; Wei Li; Alan Alfano; Hermela Shimelis; Mingyuan Chen; Angela M H Brodie; Hegang Chen; Zhen Xiao; Timothy D Veenstra; Yun Qiu
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

8.  Pim family kinases enhance tumor growth of prostate cancer cells.

Authors:  Wei Wei Chen; Daniel C Chan; Carlton Donald; Michael B Lilly; Andrew S Kraft
Journal:  Mol Cancer Res       Date:  2005-08       Impact factor: 5.852

9.  Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma.

Authors:  J Wang; J Kim; M Roh; O E Franco; S W Hayward; M L Wills; S A Abdulkadir
Journal:  Oncogene       Date:  2010-02-08       Impact factor: 9.867

Review 10.  A new trick of an old molecule: androgen receptor splice variants taking the stage?!

Authors:  Zhiyong Guo; Yun Qiu
Journal:  Int J Biol Sci       Date:  2011-07-06       Impact factor: 6.580

View more
  28 in total

Review 1.  Targeting the turnover of oncoproteins as a new avenue for therapeutics development in castration-resistant prostate cancer.

Authors:  Shan Wang; Dede N Ekoue; Ganesh V Raj; Ralf Kittler
Journal:  Cancer Lett       Date:  2018-09-11       Impact factor: 8.679

Review 2.  Implications of ubiquitin ligases in castration-resistant prostate cancer.

Authors:  Jianfei Qi; Lingling Fan; Arif Hussain
Journal:  Curr Opin Oncol       Date:  2015-05       Impact factor: 3.645

Review 3.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.

Authors:  Sabina Luszczak; Christopher Kumar; Vignesh Krishna Sathyadevan; Benjamin S Simpson; Kathy A Gately; Hayley C Whitaker; Susan Heavey
Journal:  Signal Transduct Target Ther       Date:  2020-01-31

Review 4.  Phosphorylation: a fundamental regulator of steroid receptor action.

Authors:  Lindsey S Treviño; Nancy L Weigel
Journal:  Trends Endocrinol Metab       Date:  2013-07-06       Impact factor: 12.015

5.  Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.

Authors:  Tingting Wang; Hatem Abou-Ouf; Samar A Hegazy; Mohammed Alshalalfa; Konstantin Stoletov; John Lewis; Bryan Donnelly; Tarek A Bismar
Journal:  J Mol Med (Berl)       Date:  2016-08-18       Impact factor: 4.599

6.  Pim-1 kinase as cancer drug target: An update.

Authors:  Yernar Tursynbay; Jinfu Zhang; Zhi Li; Tursonjan Tokay; Zhaxybay Zhumadilov; Denglong Wu; Yingqiu Xie
Journal:  Biomed Rep       Date:  2015-12-24

Review 7.  Mini-review: androgen receptor phosphorylation in prostate cancer.

Authors:  Garrett Daniels; Zhiheng Pei; Susan K Logan; Peng Lee
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

8.  Crosstalk between nuclear MET and SOX9/β-catenin correlates with castration-resistant prostate cancer.

Authors:  Yingqiu Xie; Wenfu Lu; Shenji Liu; Qing Yang; Brett S Carver; Estelle Li; Yuzhuo Wang; Ladan Fazli; Martin Gleave; Zhenbang Chen
Journal:  Mol Endocrinol       Date:  2014-08-06

Review 9.  Androgen receptor phosphorylation: biological context and functional consequences.

Authors:  Yulia Koryakina; Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-01-14       Impact factor: 5.678

10.  ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.

Authors:  Shuai Gao; Huihui Ye; Sean Gerrin; Hongyun Wang; Ankur Sharma; Sen Chen; Akash Patnaik; Adam G Sowalsky; Olga Voznesensky; Wanting Han; Ziyang Yu; Elahe A Mostaghel; Peter S Nelson; Mary-Ellen Taplin; Steven P Balk; Changmeng Cai
Journal:  Clin Cancer Res       Date:  2016-03-02       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.